Surveillance, Epidemiology, and End Results Program and Centers for Disease Control and Prevention cancer statistics show a sharp survival gap by stage at diagnosis. Localized and regional prostate cancer have about 100 percent five-year relative survival, while distant disease is about 40 percent. These are population statistics, not a person's prognosis.
The Surveillance, Epidemiology, and End Results Program (SEER) is a National Cancer Institute registry program that reports cancer population statistics. In SEER 21 excluding Illinois data for prostate cancer cases diagnosed from 2016 to 2022, 69% are diagnosed at a localized stage and 14% at a regional stage. Those two groups have 100% five-year relative survival. The picture changes when prostate cancer is first found after distant spread. SEER reports 40.1% five-year relative survival for distant prostate cancer, and the Centers for Disease Control and Prevention (CDC), the federal public health agency, describes the same broad pattern in U.S. Cancer Statistics.
These figures are population statistics, not medical advice and not a person's prognosis. They can provide context for questions about prostate-specific antigen (PSA) testing, referrals, biopsy timing, and communication of abnormal results, but they do not predict any one person's outcome or prove that a diagnosis was delayed.
Five-year relative survival by stage
SEER 21 excluding Illinois, prostate cancer cases diagnosed from 2016 to 2022.
| Localized | 100% |
|---|---|
| Regional | 100% |
| Distant | 40.1% |
Relative survival estimates the share of patients expected to survive the effects of cancer after accounting for other causes of death. SEER cautions that survival statistics are based on large groups and cannot predict exactly what will happen to an individual patient.
How prostate cancer is usually found
Share of prostate cancers by stage at diagnosis in SEER 21 excluding Illinois, 2016 to 2022.
| Localized | 69% |
|---|---|
| Regional | 14% |
| Distant | 9% |
| Unknown | 8% |
SEER reports 69% localized, 14% regional, 9% distant, and 8% unknown or unstaged for cases diagnosed from 2016 to 2022. CDC U.S. Cancer Statistics reports a similar stage distribution for 2019 to 2023, with 70% localized, 14% regional, and 9% distant.
How public guidance discusses PSA follow-up
This report does not recommend whether anyone should have a PSA test. The National Cancer Institute (NCI), a federal cancer research agency, explains that PSA can rise because of prostate cancer or benign conditions such as benign prostatic hyperplasia (BPH), which is noncancerous prostate enlargement, or prostatitis, which is prostate inflammation. NCI says PSA testing is used to monitor known cancer, evaluate symptoms, and screen some men without symptoms. The United States Preventive Services Task Force (USPSTF), a federal prevention panel, recommends that men ages 55 to 69 make an individual PSA screening decision after discussing benefits and harms with a clinician, and recommends against routine PSA screening for men 70 and older.
The American Cancer Society also discusses follow-up after a screening choice is made. Its guidance says men who choose screening and have PSA of 2.5 ng/mL or higher should generally be screened yearly, while some lower borderline abnormal results may be repeated after about a month and higher values may lead clinicians to discuss other tests or biopsy. The stage gap shown above is one reason public guidance treats follow-up as a clinician-patient decision, but PSA is imperfect and not every cancer behaves the same way.
When advanced disease raises questions about timing
An advanced or late prostate cancer diagnosis can sometimes follow a missed PSA result, a rising PSA that was not repeated, a delayed urology referral, a delayed biopsy, a lost imaging result, or a failure to communicate an abnormal result. That is only one possible reason for a late diagnosis. Many advanced cancers are diagnosed promptly and progress despite appropriate care.
Certain prostate cancer medications are used mainly for metastatic, castration-resistant, bone-metastatic, prostate-specific membrane antigen (PSMA) positive, or biomarker-selected advanced disease. Those medications can sometimes be a reason to ask timeline questions, but they do not prove when the cancer should have been diagnosed and they never prove negligence by themselves. If there was an earlier abnormal PSA, abnormal digital rectal exam (DRE), concerning symptom, imaging finding, or biopsy recommendation, medical records would be needed before drawing any conclusion.
New York timing rules can be strict. New York Civil Practice Law and Rules (CPLR) 214-a generally sets a medical malpractice limitations period of two years and six months, with a special cancer diagnosis rule that may depend on when the person knew or reasonably should have known of the alleged negligent act or omission and injury, subject to a seven-year cap. The exact deadline depends on the records and should be reviewed by a licensed New York attorney.
If you or someone you love was diagnosed with advanced prostate cancer, the team at Porter Law Group can review the medical records and the timeline at no cost. There is no obligation.
Methodology and sources
Survival and stage distribution figures come from the Surveillance, Epidemiology, and End Results Program (SEER), a National Cancer Institute cancer registry program. The survival chart uses SEER 21 excluding Illinois, cases diagnosed from 2016 to 2022, by SEER Combined Summary Stage. The stage distribution chart uses the SEER percentages shown with those survival data. Centers for Disease Control and Prevention (CDC) U.S. Cancer Statistics, a federal cancer surveillance source, is used as a cross-check for 2019 to 2023 stage distribution and overall survival language. Screening and follow-up context is drawn from the United States Preventive Services Task Force (USPSTF), a federal prevention panel, the National Cancer Institute (NCI), a federal cancer research agency, and the American Cancer Society. New York timing background is drawn from New York Civil Practice Law and Rules (CPLR) 214-a. This report presents aggregate public statistics only and does not evaluate any individual diagnosis, provider, or medical record.
